Prospective Registrational Trial to Define Real World Outcomes of Patients with Completely Resected Stage I or IIA Non-squamous Non-Small Cell Lung Cancer (NSCLC) Identified as High, Intermediate, or Low Risk by a 14-Gene Prognostic Assay, DetermaRXTM, being Considered for Adjuvant Platinum-based chemotherapy or other Adjuvant therapy versus Observation

Project: Clinical Trial

Project Details

StatusNot started